

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/04443 A2

(51) International Patent Classification⁷: C07D 471/00

(21) International Application Number: PCT/US01/16492

(22) International Filing Date: 25 June 2001 (25.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/217,556 12 July 2000 (12.07.2000) US

(71) Applicant (*for all designated States except US*): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SCHNUTE, Mark, E. [US/US]; 4459 Wimbledon Way, Kalamazoo, MI 49009 (US). VAILLANCOURT, Valerie, A. [US/US]; 4342 Bronson Boulevard, Kalamazoo, MI 49008 (US). LARSEN, Scott, D. [US/US]; 56 Naples Court, Kalamazoo, MI 49009 (US).

(74) Agent: YANY, Lucy, X.; Intellectual Property Legal Services, Pharmacia & Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS



(57) Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS

Background of the Invention

5 1. Field of the Invention

The present invention provides heterocycle carboxamide derivatives. These compounds are useful as antiviral agents, in particular, as agents against viruses of the herpes family.

10 2. Technology Description

The herpesviruses comprise a large family of double stranded DNA viruses. They are also a source of the most common viral illnesses in man. Eight of the herpes viruses, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and human herpes
15 viruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8), have been shown to infect humans. HSV-1 and HSV-2 cause herpetic lesions on the lips and genitals, respectively. They also occasionally cause infections of the eye and encephalitis. HCMV causes birth defects in infants and a variety of diseases in immunocompromised patients such as retinitis, pneumonia, and gastrointestinal disease. VZV is the causative agent of
20 chicken pox and shingles. EBV causes infectious mononucleosis. It can also cause lymphomas in immunocompromised patients and has been associated with Burkitt's lymphoma, nasopharyngeal carcinoma, and Hodgkins disease. HHV-6 is the causative agent of roseola and may be associated with multiple sclerosis and chronic fatigue syndrome. HHV-7 disease association is unclear, but it may be involved in
25 some cases of roseola. HHV-8 has been associated with Kaposi's sarcoma, body cavity based lymphomas, and multiple myeloma.

U.S. Patent Nos. 5,753,666 and 5,891,878 and WO 97/04775 disclose specific 1-alkyl-substituted-quinolone-3-carboxamides that are alleged to have therapeutic utility
30 via inhibition of Phosphodiesterase IV esterase and/or Tumor Necrosis factor activity.

Commonly assigned WO 00/40561 discloses quinolinecarboxamides as antiviral agents.

Commonly assigned WO 00/40563 discloses specific quinolinecarboxamides as antiviral agents.

5 Commonly assigned WO 00/53610 discloses 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents.

Commonly assigned WO99/32450 discloses specific 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents.

10 U.S. Patent No. 5,945,431 discloses specific naphthyridine heterocyclic compounds having antiviral activity that are useful in the therapy and prophylaxis of cytomegalovirus (CMV) infection in mammals.

WO99/10347 discloses specific substituted 4-oxo-naphthyridine-3-carboxamides as
15 brain receptor ligands having potential use in the treatment of central nervous system diseases and/or disorders.

WO98/19673 discloses specific heterocyclic agents for the treatment of diseases caused by viruses.

20

JP08301849 discloses specific heterocyclic agents useful as tachykinin receptor antagonists.

JP07033729 discloses specific N-cyano-N'-substituted-arylcarboxyimidamide
25 compounds exhibiting K⁺ channel opening effects and having hypotensive action and coronary vasodilating action.

WO 00/40562 discloses novel 2-oxoquinolines as selective peripheral cannabinoid receptor modulators).

30

WO 97/34894 discloses Naphthyridine derivatives and their analogues inhibiting cytomegalovirus.

Despite the above teachings, there still exists a need in the art for novel compounds that demonstrate desirable antiviral activity.


Brief Summary of the Invention

5

In accordance with the present invention, novel compounds which demonstrate antiviral activity are provided. More specifically, the compounds are specific heterocycle carboxamide derivatives which are useful as antiviral agents, particularly against herpes viruses.

10

Even more specifically, the present invention provides a compound of formula I,



15

(I)

wherein,

X is Cl, Br, F, CN or NO₂;

G is (a) C₁₋₇alkyl which is partially unsaturated and is substituted by hydroxy, or
(b) C₁₋₄alkyl substituted by NR¹R² or 4-tetrahydropyran;

20


R¹ is C₂₋₇alkyl substituted by hydroxy, C₁₋₄alkoxy, aryl, or heteroaryl;

R² is hydrogen or C₁₋₇alkyl;

or R¹ and R² together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C₁₋₇alkyl;

W is a heterocycle of formula W1, W3, or W4;

25



A is CR⁴ or nitrogen;

30

B is CR⁵ or nitrogen;

C is CR⁶ or nitrogen;

E and F are such that

- (a) one is oxygen and the other is C(=O); or
(b) E is C(=O) and F is NR⁷;

- J and K are such that
- (a) J is nitrogen and K is CR⁸; or
 - (b) J is CR⁶ and K is nitrogen;

with the provisos that when W is of formula W3 and J is nitrogen, then at least one of A and B is nitrogen;

- 5 R⁴ is H, halogen, or C₁₋₄alkyl optionally substituted by one to three halogens;

R⁵ is (a) H,

(b) halo,

(c) OR¹²,

(d) SR¹²,

- 10 (e) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,

(f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,

- 15 (g) (C=O)R⁹,

(h) S(O)_mR⁹,

(i) (C=O)OR²,

(j) NHSO₂R⁹,

(k) nitro, or

- 20 (l) cyano;

R⁶ is (a) H,

(b) halo,

(c) aryl,

(d) het,

- 25 (e) OR¹²,

(f) SR¹²,

(g) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, aryl, halo, C₃₋₈cycloalkyl optionally substituted by OR¹², or het attached through a carbon atom,

30

(h) NR¹⁰R¹¹,

- (i) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,
- (j) (C=O)R⁹,
- 5 (k) S(O)_mR⁹,
- (l) (C=O)OR²,
- (m) NHSO₂R⁹,
- (n) nitro, or
- (o) cyano;
- 10 R⁷ is (a) H,
- (b) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
- (c) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,
- 15 (d) aryl, or
- (e) het;
- R⁸ is (a) H,
- (b) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
- 20 (c) OR¹², or
- (d) SR¹²;
- R⁹ is (a) C₁₋₇alkyl,
- (b) NR¹⁰R¹¹,
- 25 (c) aryl, or
- (d) het, wherein said het is bound through a carbon atom;
- R¹⁰ and R¹¹ are independently
- (a) H,
- (b) aryl,
- 30 (c) C₁₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR²R², CO₂R², het, aryl, cyano, or halo,

(d) C₂₋₇alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR²R², OR², or SR²,

(e) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R², or

(f) R¹⁰ and R¹¹ together with the nitrogen to which they are attached form a het;

R¹² is (a) H,

(b) aryl,

(c) het

(d) C₁₋₇alkyl optionally substituted by aryl, het, or halogen,

(e) C₂₋₇alkyl substituted by OR², SR², or NR²R², or

(f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R²;

each m is independently 1 or 2;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR²R², CO₂R², CF₃, C₁₋₆alkoxy, and C₁₋₆alkyl which maybe further substituted by one to three SR², NR²R², OR², or CO₂R² groups;

het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO₂R², CF₃, C₁₋₆alkoxy, oxo, oxime, and C₁₋₆alkyl which may be further substituted by one to three SR², NR²R², OR², or CO₂R² groups;

halo or halogen is F, Cl, Br, I;

1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);

and pharmaceutically acceptable salts thereof.

In particularly preferred embodiments, X is Cl and G is 4-morpholinylmethyl.

Another embodiment of the present invention provides a pharmaceutical composition comprising a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In preferred
5 embodiments, the composition preferably comprises a therapeutically effective amount of the compound or salt.

Still another embodiment of the present invention provides a method for treating a disease or condition in a mammal caused by a viral infection, particularly a herpes
10 viral infection, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. For this embodiment, in addition to the compounds encompassed by formula (I), G can also represent C₁₋₇alkyl which is fully saturated and is substituted by hydroxy.

15 A further embodiment of the present invention comprises the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating or preventing diseases or disorders caused by a viral infection, and particularly a herpes viral infection.

20 A final embodiment of the present invention comprises a method for inhibiting a viral DNA polymerase, comprising contacting (in vitro or in vivo) the polymerase with an effective inhibitory amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

25 An object of the present invention is to provide novel compounds having biological activity.

A further object of the present invention is to provide novel pharmaceutical compositions.

30 Still another object of the present invention is to provide a method for treating a disease or condition in a mammal caused by a viral infection, particularly a herpes virus infection.

Another object of the present invention is to provide a method for inhibiting a viral DNA polymerase.

These, and other objects, will readily be apparent to those skilled in the art as
5 reference is made to the detailed description of the preferred embodiment.

Detailed Description of the Preferred Embodiment

In describing the preferred embodiment, certain terminology will be utilized for the sake of clarity. Such terminology is intended to encompass the recited embodiment,
10 as well as all technical equivalents which operate in a similar manner for a similar purpose to achieve a similar result.

1. Terminology Definitions

The following definitions are used, unless otherwise described: halo is fluoro, chloro,
15 bromo, or iodo. Alkyl denotes both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to. When alkyl can be partially unsaturated, the alkyl chain may comprise one or more (e.g., 1, 2, 3, or 4) double or triple bonds in the chain.

20

Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic. Het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated ring containing 1, 2 or 3 heteroatoms selected from the group consisting of non-peroxide oxygen, sulfur, and nitrogen, which is
25 optionally fused to a benzene ring, or any bicyclic heterocyclic group. Het includes "heteroaryl", which encompasses a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and 1, 2, 3, or 4 heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, C₁₋₄alkyl, phenyl or benzyl.

30

It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the

present invention encompasses any racemic, optically-active, polymorphic, tautomeric, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine antiviral activity using the standard tests described herein, or using other similar tests which are well known in the art.

10 The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating a lower and upper number of carbon atoms in the moiety, i.e., the prefix C_{i-j} indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus, for example, C₁₋₇alkyl refers to alkyl of one to seven carbon atoms, inclusive.

15

The compounds of the present invention are generally named according to the IUPAC or CAS nomenclature system. Abbreviations which are well known to one of ordinary skill in the art may be used (e.g. "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "h" for hour or hours and "rt" for room temperature).

20

Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents. The compounds of the invention include compounds of formula (I) having any combination of the values, specific values, more specific values, and preferred values described herein.

25

Mammal denotes human and animals, specifically including food animals and companion animals.

30 2. The Invention


The present invention comprises compounds of formula (I) as defined above, and their pharmaceutically acceptable salts.

For the compounds of formula (I), alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, hexyl, heptyl, etc.; C₃₋₈cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, hexyloxy, 1-methylhexyloxy, or heptyloxy; het can be azetidiny, 3,3-dihydroxy-1-azetiny, pyrrolidino, piperidino, morpholino, thiomorpholino, or heteroaryl; and heteroaryl can be furyl, imidazolyl, triazolyl, triazinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N-oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N-oxide) or quinolyl (or its N-oxide).


When alkyl is partially unsaturated, it can be vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 1-pentylnyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 5-hexene-1-ynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl.

Specific examples of W1 include,


20



25




30







W1.13




W1.14




W1.15




W1.16




W1.17




W1.18




W1.19




W1.20



W1.21




W1.22




W1.23


Specific examples of W3 include,




W3.1




W3.2




W3.3




W3.4




W3.5




W3.6




W3.7




W3.8




W3.9




W3.10




W3.11



W3.12



W3.13



W3.14

Particularly preferred compounds are those where X is Cl and G is 4-morpholinylmethyl.

Examples of the present invention include, but are not limited to the following:

5 *N*-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-2-oxo-2*H*-pyrano[2,3-
c]pyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1*H*-isochromene-3-
carboxamide;

10 *N*-(4-chlorobenzyl)-4-hydroxy-1-oxo-6-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-
isochromene-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1*H*-isochromene-3-
carboxamide;

15

N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)-8-oxo-7,8-dihydro[1,7]-
naphthyridine-6-carboxamide;

20 *N*-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1,2-dihydro-3-
isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1,2-dihydro-3-
isoquinolinecarboxamide;

25 *N*-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]naphthyridine-3-
carboxamide;

N-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]-
naphthyridine-3-carboxamide;

30

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-
carboxamide;

- N*-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-carboxamide;
- 5 *N*-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,5]naphthyridine-3-carboxamide;
- N*-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,5]naphthyridine-3-carboxamide;
- 10 *N*-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2*H*-pyran-4-ylmethyl)[1,5]-naphthyridine-3-carboxamide;
- N*-(4-chlorobenzyl)-8-hydroxy-2-(3-hydroxy-1-propynyl)pyrido[3,2-*d*]pyrimidine-7-carboxamide;
- 15 *N*-(4-chlorobenzyl)-8-hydroxy-2-(4-morpholinylmethyl)pyrido[3,2-*d*]pyrimidine-7-carboxamide;
- N*-(4-chlorobenzyl)-5-hydroxy-3-(4-morpholinylmethyl)[1,7]naphthyridine-6-carboxamide;
- 20 *N*-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)[1,7]naphthyridine-6-carboxamide;
- N*-(4-chlorobenzyl)-5-hydroxy-3-(tetrahydro-2*H*-pyran-4-ylmethyl)[1,7]-naphthyridine-6-carboxamide;
- 25 *N*-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-isoquinolinecarboxamide;
- 30 *N*-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-3-isoquinolinecarboxamide;
- N*-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2*H*-pyran-4-ylmethyl)-3-isoquinolinecarboxamide; and

pharmaceutically acceptable salts thereof.


Representative examples of the synthesis of compounds falling within the scope of
5 formulas W1, W3, or W4 are as follows.

The following Charts A – S describe the preparation of the compounds of the present invention. All of the starting materials are prepared by procedures described in these charts or by procedures analogous thereto, which would be well known to one of
10 ordinary skill in organic chemistry. All of the final compounds of the present invention are prepared by procedures described in these charts or by procedures analogous thereto, which would be well known to one of ordinary skill in organic chemistry. All of the variables used in the charts are as defined below or as in the claims.

15

W1.3. 4-Hydroxy-2-oxo-2H-pyrano[2,3-c]pyridine-3-carboxamides. Preparation of specific examples of heterocycle W1.3 follows an established precedent for the corresponding ring synthesis (*Bull. Soc. Chim. Fr.* **1979**, 289), Chart A. 3-Hydroxy-6-methyl-4-pyridinecarboxylic acid **A.1** (JP 45016705) is reacted with ethyl
20 chloroformate followed by ethoxymagnesium diethylmalonate and potassium carbonate to afford the pyranopyridine **A.2**. Benzylic halogenation mediated by *N*-bromosuccinimide and AIBN affords the halide **A.3** which undergoes displacement with a substituted amine (e.g. morpholine) to afford **A.4**. The resulting ester **A.4** is then saponified to afford the corresponding carboxylic acid **A.5** which is then coupled
25 with a benzylamine (e.g. 4-chlorobenzylamine, 4-bromobenzylamine, or 4-fluorobenzylamine) mediated by 1,1'-carbonyldiimidazole (or other suitable carboxylic acid activating agent) to provide amides of the general formula **A.6**.

CHART A



- 10 W1.9. 4-Hydroxy-1-oxo-1H-isochromene-3-carboxamides. Preparation of specific examples of heterocycle W1.9 follows established precedent for 1-oxo-1H-isochromene ring synthesis (*Indian J. Chem., B.* **1983**, 22, 349-351; *Indian J. Chem., B.* **1986**, 25, 189-190.), Chart B. Benzolactones of the formula **B.1** are prepared as described in Chart C (Y = morpholinylmethyl or 4-tetrahydropyranylmethyl), or are
- 15 prepared according to literature procedures (Y = iodo; *J. Chem. Soc.* **1931**, 867-871.). **B.1** is condensed with oxalic acid diethyl ester in the presence of sodium ethoxide to afford isochromene **B.2**. The resulting ester **B.2** is then saponified to afford the corresponding carboxylic acid **B.3** which is then coupled with a benzylamine (e.g. 4-chlorobenzylamine, 4-bromobenzylamine, or 4-fluorobenzylamine) mediated by 1,1'-
- 20 carbonyldiimidazole (or other suitable carboxylic acid activating agent) to provide amides of the general formula **B.4**. **B.1** (Y = morpholinylmethyl) is prepared according to Chart C. Reductive amination of **C.1** (*J. Chem. Soc.* **1925**, 2275-2295) with morpholine, acetic acid, and sodium triacetoxyborohydride provides the morpholine derivative **B.1** (Y = morpholinylmethyl). Similarly, **B.1** (Y = 4-
- 25 tetrahydropyranylmethyl) is prepared according to Chart C. Wittig olefination between **C.1** and 4-tetrahydropyranylphosphonium bromide (Bestmann, H. J.; Stransky, W.; Vostrowsky, O. *Chem. Ber.* **1979**, 109, 1694-1700.) employing sodium hexamethyldisilazide as base provides the olefin **C.2**. Hydrogenation of **C.2** catalyzed by palladium on carbon provides **B.1** (Y = 4-tetrahydropyranylmethyl).

30

CHART B





CHART C




Where Y = iodo, the products of Chart B (B.4, Y = iodo) may be further elaborated as described in Chart D. Sonogashira coupling of B.4 (Y = iodo) with an electron-rich acetylene (e.g. propargyl alcohol, Z = CH₂OH) catalyzed by PdCl₂(PPh₃)₂ and copper(I) iodide either in diethylamine (Sonogashira, K.; Tohada, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, *50*, 4467.) or in a mixture of DMF and triethylamine (Fisher, M. J. et. al. *J. Med. Chem.* **1997**, *40*, 2085.) provides the corresponding alkynyl derivatives of formula D.1 (Z = CH₂OH). Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives of formula D.2 (Z = CH₂OH).

20

25


CHART D



W1.17. 5-Hydroxy-8-oxo-7,8-dihydro[1,7]naphthyridine-6-carboxamides. Preparation of specific examples of heterocycle W1.17 follows an established literature

precedent described in Chart E (*J. Heterocyclic Chem.* 1996, 33, 361.). Cyclic anhydride **E.1** prepared as described in the literature (*J. Org. Chem.* 1961, 26, 808.) is reacted with acetamide and acetic anhydride (*J. Med. Chem.* 1989, 32, 2116.) to afford succinimide derivative **E.2**. Coupling of **E.2** with a substituted *N*-benzyl-2-chloroacetamide (e.g. *N*-(4-chlorobenzyl)-chloroacetamide prepared as described in US Patent 5,834,514) in the presence of an appropriate base affords the substituted imide derivative of the formula **E.3**. Compounds of the formula **E.3** undergo rearrangement when treated with ethoxide to afford naphthyridines of the formula **E.4**. Sonogashira coupling of **E.4** with an electron-rich acetylene (e.g. propargyl alcohol, $Z = \text{CH}_2\text{OH}$) catalyzed by $\text{PdCl}_2(\text{PPh}_3)_2$ and copper(I) iodide either in diethylamine (Sonogashira, K.; Tohada, Y.; Hagihara, N. *Tetrahedron Lett.* 1975, 50, 4467.) or in a mixture of DMF and triethylamine (Fisher, M. J. et. al. *J. Med. Chem.* 1997, 40, 2085.) provides the corresponding alkynyl derivatives of formula **E.5** ($Z = \text{CH}_2\text{OH}$). Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives of formula **E.6** ($Z = \text{CH}_2\text{OH}$).


CHART E



W1.21. 4-Hydroxy-1-oxo-1,2-dihydro-3-isoquinolinecarboxamides. Preparation of specific examples of heterocycle W1.21 follows an established literature precedent set forth in *J. Heterocyclic Chem.* 1985, 22, 577. and elaborated on in Charts F and G

below. Examples in which G = 3-hydroxypropyl or 3-hydroxy-1-propynyl are prepared as described in Chart F. Cyclic anhydride **F.1** is reacted with acetamide and acetic anhydride as described in the literature (*Bull. Chem. Soc. Japan* **1957**, *30*, 958.) to afford succinimide derivative **F.2**. Coupling of **F.2** with a substituted *N*-benzyl-2-chloroacetamide (e.g. *N*-(4-chlorobenzyl)-chloroacetamide prepared as described in US Patent 5,834,514) in the presence of an appropriate base affords the substituted imide derivative of the formula **F.3**. Compounds of the formula **F.3** undergo rearrangement when treated with ethoxide to afford naphthyridines of the formula **F.4**. Sonogashira coupling of **F.4** with an electron-rich acetylene (e.g. propargyl alcohol, Z = CH₂OH) catalyzed by PdCl₂(PPh₃)₂ and copper(I) iodide either in diethylamine (Sonogashira, K.; Tohada, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, *50*, 4467.) or in a mixture of DMF and triethylamine (Fisher, M. J. et. al. *J. Med. Chem.* **1997**, *40*, 2085.) provides the corresponding alkynyl derivatives of formula **F.5** (Z = CH₂OH). Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives of formula **F.6** (Z = CH₂OH).


CHART F



Compounds such as those in which G = morpholinylmethyl are prepared as described in Chart G. Diester **G.1** (*J. Am. Chem. Soc.* **1996**, *118*, 8847) undergoes displacement with morpholine to afford morpholinylmethyl derivative **G.2**. Saponification of **G.2** to afford the corresponding diacid followed by cyclic anhydride formation by heating


with acetic anhydride (*Org. Syn. Coll.* **1941**, *1*, 410) affords **G.4**. Succinimide **G.5** is then formed by reacting **G.4** with ammonium carbonate in aq. ammonium hydroxide (*Org. Syn. Coll.* **1941**, *1*, 457). Coupling of **G.5** with a substituted *N*-benzyl-2-chloroacetamide (e.g. *N*-(4-chlorobenzyl)-chloroacetamide) in the presence of an appropriate base affords the substituted imide derivative of the formula **G.6**.
 5 Compounds of the formula **G.6** undergo rearrangement when treated with ethoxide to afford derivatives of the formula **G.7**.

CHART G



W3.1. 4-Oxo-1,4-dihydro[1,7]naphthyridine-3-carboxamides. The preparation of representative examples of heterocycle W3.1 is described in Chart H. Condensation of 3-aminopyridine-*N*-oxide **H.1** with diethyl ethoxymethylenemalonate followed by
 25 cyclization provides 1,7-naphthyridine-3-carboxylate **H.2** (*J. Org. Chem.* **1954**, 2008). Condensation of the resulting ester with 4-chlorobenzylamine at elevated temperatures provides the corresponding benzyl amide **H.3**. Reduction of the *N*-oxide followed by treatment with POBr_3 affords 6-bromo-1,7-naphthyridine **H.4**. Sonogashira coupling of **H.4** with an electron-rich acetylene (e.g. propargyl alcohol)
 30 affords the alkynyl derivatives such as **H.5**. Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives such as **H.6**.

CHART H




Specific examples of heterocycle W3.1 in which $R^6 = OCH_2CH_3$ are prepared as described in Chart I. 3-Amino-6-bromo-2-ethoxypyridine **I.1** is condensed with

15 diethyl ethoxymethylenemalonate, and the resulting enamine is cyclized thermally to provide naphthyridine ester **I.2**. Saponification of the ester followed by coupling of the resulting carboxylic acid with a benzylamine (e.g. 4-chlorobenzylamine) mediated by 1,1'-carbonyldiimidazole (or other suitable carboxylic acid activating agent) provides amides of the general formula **I.3**. Sonogashira coupling of **I.3** with an

20 electron-rich acetylene (e.g. propargyl alcohol) provides alkynyl-derivatives of the formula **I.4**. Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives of the formula **I.5**.


CHART I



Specific examples of heterocycle W3.1 in which $G = \text{CH}_2\text{NR}^1\text{R}^2$ are prepared as described in Chart J. The aryl bromides prepared above in Charts H and I (**H.4** and **I.3**) undergo palladium catalyzed carbonylation in the presence of tributyltin hydride to give the corresponding aldehydes of the formula **J.1**. Reductive amination with a primary or secondary amine (e.g. morpholine) and sodium cyanoborohydride affords derivatives of the formula **J.2**.

20


CHART J



30 W3.2. 4-Oxo-1,4-dihydro[1,5]naphthyridine-3-carboxamides. Preparation of specific examples of heterocycle W3.2 follows established precedent for [1,5]naphthyridine ring synthesis (US patent 3,225,055; *Eur. J. Med. Chem.* **1977**, *12*, 549; *J. Chem. Soc., C.* **1954**, 2357-2361.), Chart K. 3-Aminopyridines **K.1** (Y = morpholinylmethyl

or tetrahydropyranylmethyl) prepared as described in Chart P are condensed with diethyl ethoxymethylenemalonate to afford enamines of the formula **K.2**. Thermal cyclization in refluxing diphenyl ether provides the 1,4-dihydro[1,5]naphthyridine-3-esters **K.3**. The resulting ester is then treated with a benzylamine (e.g. 4-chlorobenzylamine, 4-bromobenzylamine, or 4-fluorobenzylamine) at high temperature to afford the corresponding amides of the general formula **K.4** or, alternatively, ester **K.3** may be saponified to afford the corresponding acid which is then coupled with a benzylamine mediated by 1,1'-carbonyldiimidazole (or other suitable carboxylic acid activating agent) to likewise provide amides of the general formula **K.4** or, alternatively, ester **K.3** may be treated with an above benzylamine and trimethylaluminum in an appropriate solvent to provide amides of the general formula **K.4**.


CHART K



K.1 (Y = morpholinylmethyl) is prepared according to Chart L. Reductive amination of 5-nitro-2-pyridine carboxaldehyde (**L.1**) with morpholine, acetic acid, and sodium triacetoxyborohydride provides the pyridylmethylmorpholine **L.2**. Reduction of the nitro group in **L.2** employing hydrogenation catalyzed by palladium on carbon provides **K.1** (Y = morpholinylmethyl). Similarly, **K.1** (Y = 4-tetrahydropyranylmethyl) is prepared according to Chart L. Wittig olefination between **L.1** and 4-tetrahydropyranylphosphonium bromide (Bestmann, H. J.; Stransky, W.; Vostrowsky, O. *Chem. Ber.* **1979**, *109*, 1694-1700.) employing sodium hexamethyldisilazide as base provides the olefin **L.3**. Hydrogenation of **L.3** catalyzed by palladium on carbon provides **K.1** (Y = 4-tetrahydropyranylmethyl).

25
 30


CHART L



As further described in Chart K for the case where Y = chloro, the enamine **K.2** is prepared as described in the literature (J. Heindl et al., *Eur. J. Med. Chem. Chim. Ther.* **1977**, *12*, 549-555). Thermal cyclization in refluxing diphenyl ether provides the 1,4-dihydro[1,5]naphththyridine-3-ester **K.3**. The product **K.3** (Y = chloro) may be further elaborated as described in Chart M. Sonogashira coupling of **K.3** (Y = chloro) with an electron-rich acetylene (e.g. propargyl alcohol) catalyzed by $\text{PdCl}_2(\text{PPh}_3)_2$ and copper(I) iodide either in diethylamine (Sonogashira, K.; Tohada, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, *50*, 4467.) or in a mixture of DMF and triethylamine (Fisher, M. J. et. al. *J. Med. Chem.* **1997**, *40*, 2085.) provides the corresponding alkynyl derivatives of formula **M.1** (Z = CH_2OH). The resulting ester is then treated with a benzylamine (e.g. 4-chlorobenzylamine, 4-bromobenzylamine, or 4-fluorobenzylamine) and trimethylaluminum in an appropriate solvent to provide amides of the general formula **M.2**. Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives of formula **M.3** (Z = CH_2OH).


25

CHART M



W3.4. 8-Hydroxypyrido[3,2-*d*]pyrimidine-7-carboxamides. Preparation of specific examples of heterocycle W3.4 follows an established literature precedent described in Chart N (US Patent 3,320,257 and *J. Chem. Soc. C.* **1967**, 1745.). Heteroarylamine N.1 (*Coll. Czech. Chem. Commun.* **1975**, 40, 1396-1402.) is condensed with diethyl ethoxymethylenemalonate to afford the enamine N.2. Cyclization of N.2 is effected by heating the enamine in diethylphthalate to provide bicycle N.3. The resulting ester N.3 is then saponified to afford the corresponding carboxylic acid N.4 which is then coupled with a benzylamine (e.g. 4-chlorobenzylamine, 4-bromobenzylamine, or 4-fluorobenzylamine) mediated by 1,1'-carbonyldiimidazole (or other suitable carboxylic acid activating agent) to provide amides of the general formula N.5. Sonogashira coupling of N.5 with an electron-rich acetylene (e.g. propargyl alcohol) catalyzed by $\text{PdCl}_2(\text{PPh}_3)_2$ and copper(I) iodide either in diethylamine (Sonogashira, K.; Tohada, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, 50, 4467.) or in a mixture of DMF and triethylamine (Fisher, M. J. et. al. *J. Med. Chem.* **1997**, 40, 2085.) provides the corresponding alkynyl derivatives of formula N.6 ($\text{Z} = \text{CH}_2\text{OH}$). Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives of formula N.7 ($\text{Z} = \text{CH}_2\text{OH}$).


CHART N



Alternatively, derivatives where $\text{G} = \text{CH}_2\text{NR}^1\text{R}^2$ (e. g. 4-morpholinomethyl) are prepared from N.5 as described in Chart O. Compounds of the formula N.5 undergo palladium catalyzed carbon monoxide insertion and trapping with methanol to afford


methyl esters of the formula **O.1**. The resulting esters are reduced with lithium
 aluminum hydride or other suitable reducing agent to provide the corresponding
 alcohols of the formula **O.2**. Activation of the alcohol as the mesylate by reaction
 with methanesulfonyl chloride in the presence of an amine base (e.g. collidine)
 5 followed by displacement with a primary or secondary amine (HNR^1R^2 such as
 morpholine) provides compounds of the formula **O.3**.

CHART O




W3.6. 5-Hydroxy-[1,7]naphthyridine-6-carboxamides. Preparation of specific
 examples of heterocycle W3.6 follows established precedent for 5-hydroxy--
 [1,7]naphthyridine ring synthesis (*Just. Liebigs.* **1979**, 443-445.), Chart P. 5-Iodo-2-
 methylpyridine-3-carboxylic acid (**P.1**) (*J. Am. Chem. Soc.* **1953**, 75, 737) is
 20 brominated under radical conditions (e.g. NBS, benzoylperoxide) to afford pyridine
P.2. **P.2** is treated with ethyl 2-*N*-toluenesulfonylaminoacetate to provide **P.3**. Upon
 treatment of **P.3** with ethoxide in ethanol, ring cyclization and elimination occurs to
 afford naphthyridine **P.4**. The resulting ester is then treated with a benzylamine (e.g.
 4-chlorobenzylamine, 4-bromobenzylamine, or 4-fluorobenzylamine) at high
 25 temperature to afford the corresponding amides of the general formula **P.5** or,
 alternatively, ester **P.4** is saponified to afford the corresponding acid which is then
 coupled with a benzylamine employing standard amide coupling protocols (e.g.
 HOBT/EDC or other suitable carboxylic acid activating agent) to likewise provide
 amides of the general formula **P.5**.

CHART P



- Intermediate **P.5** may be further elaborated as described in Chart Q to prepare derivatives where according to formula (I) $G = 3\text{-hydroxy-1-propynyl}$ and 3-hydroxypropyl . Sonogashira coupling of halide **P.5** with an electron-rich acetylene (e.g. propargyl alcohol, $Z = \text{CH}_2\text{OH}$) catalyzed by $\text{PdCl}_2(\text{PPh}_3)_2$ and copper(I) iodide either in diethylamine (Sonogashira, K.; Tohada, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, *50*, 4467.) or in a mixture of DMF and triethylamine (Fisher, M. J. et. al. *J. Med. Chem.* **1997**, *40*, 2085.) provides the corresponding alkynyl derivatives of formula **Q.1** ($A = \text{N}$, $Z = \text{CH}_2\text{OH}$). Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives of formula **Q.2** ($A = \text{N}$, $Z = \text{CH}_2\text{OH}$).


CHART Q



- Intermediate **P.5** may be further elaborated as described in Chart R to prepare derivatives where $G = \text{morpholinylmethyl}$. Carbon monoxide insertion under reductive conditions (J. K. Stille *J. Am. Chem. Soc.* **1986**, *108*, 452-461.) catalyzed by a palladium catalyst (e.g. $\text{Pd}(\text{OAc})_2$, $\text{PdCl}_2(\text{PPh}_3)_2$) provides carboxaldehyde **R.1**. Reductive amination of **R.1** with morpholine, acetic acid, and sodium triacetoxyborohydride provides the pyridylmethylmorpholine **R.2**. The intermediate


R.1 may also be further elaborated as described in Chart R to prepare derivatives where G = 4-tetrahydropyranylmethyl. Wittig olefination between R.1 and 4-tetrahydropyranylphosphonium bromide (Bestmann, H. J.; Stransky, W.; Vostrowsky, O. *Chem. Ber.* **1979**, *109*, 1694-1700.) employing sodium hexamethyldisilazide as
 5 base provides the olefin R.3. Hydrogenation of R.3 catalyzed by palladium on carbon provides R.4.

CHART R



W3.7. 4-Hydroxy-3-isoquinolinecarboxamides. Preparation of specific examples of
 20 heterocycle W3.7 follows established precedent for 4-hydroxy-3-isoquinoline ring synthesis (*Tetrahedron* **1985**, *41*, 6063.), Chart S. 3-Bromobenzoic acid-6-carboxaldehyde (S.1) (US Patent 3,465,003) is reacted with 2-aminoacetic acid diethyl boronate to afford imine S.2. S.2 is treated with potassium tert-butoxide and dimethylsulfate followed by additional potassium tert-butoxide and the resulting
 25 product is acidified to afford isoquinoline S.3. The resulting carboxylic acid is then coupled with a benzylamine (e.g. 4-chlorobenzylamine, 4-bromobenzylamine, or 4-fluorobenzylamine) employing standard amide coupling protocols (e.g. HOBT, EDC) to afford the corresponding amides of the general formula S.4.

CHART S



As described in Chart Q, Sonogashira coupling of halide S.4 with an electron-rich acetylene (e.g. propargyl alcohol, Z = CH₂OH) catalyzed by PdCl₂(PPh₃)₂ and copper(I) iodide either in diethylamine (Sonogashira, K.; Tohada, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, *50*, 4467.) or in a mixture of DMF and triethylamine (Fisher, M. J. et. al. *J. Med. Chem.* **1997**, *40*, 2085.) provides the corresponding alkynyl derivatives of formula Q.1 (A = CH, Z = CH₂OH). Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives of formula Q.2 (A = CH, Z = CH₂OH). Intermediate S.4 may be further elaborated as described in Chart R to prepare derivatives where G = morpholinylmethyl. Carbon monoxide insertion under reductive conditions (J. K. Stille *J. Am. Chem. Soc.* **1986**, *108*, 452-461.) catalyzed by a palladium catalyst (e.g. Pd(OAc)₂, PdCl₂(PPh₃)₂) provides carboxaldehyde R.1 (A = CH). Reductive amination of R.1 (A = CH) with morpholine, acetic acid, and sodium triacetoxyborohydride provides the pyridylmorpholine R.2 (A = CH). The intermediate R.1 may also be further elaborated to prepare derivatives where G = 4-tetrahydropyranylmethyl. Wittig olefination between R.1 (A = CH) and 4-tetrahydropyranylphosphonium bromide (Bestmann, H. J.; Stransky, W.; Vostrowsky, O. *Chem. Ber.* **1979**, *109*, 1694-1700.) employing sodium hexamethyldisilazide as base provides the olefin R.3 (A = CH). Hydrogenation of R.3 (A = CH) catalyzed by palladium on carbon provides R.4 (A = CH).

The inventive compounds may be used in their native form or as salts. In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of

pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, etoglutarate, and glycerophosphate. Suitable inorganic salts may also be formed,
5 including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal
10 (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

Compounds of the present invention can conveniently be administered in a pharmaceutical composition containing the compound in combination with a suitable
15 excipient, the composition being useful in combating viral infections. Pharmaceutical compositions containing a compound appropriate for antiviral use are prepared by methods and contain excipients which are well known in the art. A generally recognized compendium of such methods and ingredients is Remington's Pharmaceutical Sciences by E.W. Martin (Mark Publ. Co., 15th Ed., 1975). The compounds
20 and compositions of the present invention can be administered parenterally (for example, by intravenous, intraperitoneal or intramuscular injection), topically (including but not limited to surface treatment, transdermal application, and nasal application), intravaginally, orally, or rectally, depending on whether the preparation is used to treat internal or external viral infections.

25

For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the
30 compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained. -

The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices such as the osmotic release type devices developed by the Alza Corporation under the OROS trademark.

The compounds or compositions can also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

Pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example,

glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various
5 antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the
10 compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients
15 enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

20

For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

25

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic
30 surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers. Thickeners

such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

5

Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

10

Useful dosages of the compounds of formula I can be determined by comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

15

The compound is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form. The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, 20 for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

25

For internal infections, the compositions can be administered orally or parenterally at dose levels, calculated as the free base, of about 0.1 to 300 mg/kg, preferably 1.0 to 30 mg/kg of mammal body weight, and can be used in man in a unit dosage form, administered one to four times daily in the amount of 1 to 1000 mg per unit dose.

30

For parenteral administration or for administration as drops, as for eye infections, the compounds are presented in aqueous solution in a concentration of from about 0.1 to about 10%, more preferably about 0.1 to about 7%. The solution may contain other ingredients, such as emulsifiers, antioxidants or buffers.

Generally, the concentration of the compound(s) of formula I in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will
5 be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.

The exact regimen for administration of the compounds and compositions disclosed herein will necessarily be dependent upon the needs of the individual subject being treated, the type of treatment and, of course, the judgment of the attending
10 practitioner. The compounds of the present invention can be administered to an animal in need of treatment. In most instances, this will be a human being, but the treatment of livestock and companion animals is also specifically contemplated as falling within the scope of the instant invention.

15 The compounds of formula (I) and pharmaceutically acceptable salts thereof are useful as antiviral agents. Thus, they are useful to combat viral infections in animals, including man. The compounds are generally active against herpes viruses, and are particularly useful against the varicella zoster virus, the Epstein-Barr Virus, the herpes simplex virus types 1 and 2 (HSV-1 and 2), the human herpes virus types 6, 7 and 8
20 (HHV-6, 7 and 8) and the human cytomegalovirus (HCMV).

The invention will be further described by the following non-limiting examples.

Preparation 1

25 Ethyl 6-Chloro-4-hydroxy[1,5]naphthyridine-3-carboxylate (K.3, Y = Cl).

A solution of diethyl 2-(((6-chloro-3-pyridinyl)amino)methylene)malonate (J. Heindl et al., *Eur. J. Med. Chem. Chim. Ther.* 1977, 12, 549-555) (1.00 g) in diphenyl ether (110 mL) is degassed by three cycles of evacuation and nitrogen purging at room
30 temperature. The solution is heated rapidly to reflux and stirred for 15 minutes. After cooling, the mixture is diluted with diethyl ether (150 mL), stirred vigorously for 5 minutes, and then filtered. The collected solid is washed repeatedly with ether and then dried under vacuum, affording 0.711 g (84%) of the title compound as a beige

powder. Physical characteristics: ^1H NMR ($\text{DMSO}-d_6$) δ 8.61, 8.12, 7.79, 4.23, 1.29; HRMS (FAB) calcd for $\text{C}_{11}\text{H}_9\text{ClN}_2\text{O}_3 + \text{H}$ m/z 253.0380, found 253.0387. Anal. Calcd for $\text{C}_{11}\text{H}_9\text{ClN}_2\text{O}_3$: C, 52.29; H, 3.59; N, 11.09; Cl, 14.03. Found: C, 52.25; H, 3.53; N, 11.23

5

Preparation 2

Ethyl 4-Hydroxy-6-(3-hydroxy-1-propynyl)[1,5]naphthyridine-3-carboxylate (M.1, Z = CH_2OH)


- 10 Triethylamine (10 mL) is added to dry cuprous iodide (52 mg) under nitrogen. The mixture is stirred for 5 minutes. Propargyl alcohol (50 μL) is added. After stirring another 5 minutes, dichlorobis(triphenylphosphine)palladium(II) (48 mg) is added. The mixture is again stirred for 5 minutes before the addition of ethyl 6-chloro-4-hydroxy[1,5]naphthyridine-3-carboxylate (Preparation 1, 348 mg) and DMF (10 mL).
- 15 After stirring another 5 minutes, the remaining propargyl alcohol (660 μL) is added, and the reaction is tightly capped and stirred at 70 $^\circ\text{C}$ for 11 hours. After cooling, the mixture is diluted with ether (75 mL), sonicated to break up any solids, and filtered. The collected solid is washed with ether, dried under vacuum and recrystallized from ethanol.

20

Example 1

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,5]naphthyridine-3-carboxamide (M.2, Z = CH_2OH , X = Cl)

25



30

Trimethylaluminum (2M in toluene, 42 μL) is added dropwise to a room temperature solution of 4-chlorobenzylamine (17 μL) in CH_2Cl_2 (1 mL) under nitrogen. The solution is stirred for 5 minutes before the addition in one portion of ethyl 4-hydroxy-6-(3-hydroxy-1-propynyl)[1,5]naphthyridine-3-carboxylate (Preparation 2, 19 mg). The reaction is stirred at room temperature for 3.5 h. The reaction mixture is partitioned with dil. aq. HCl (2 mL) and extracted with CH_2Cl_2 (2 x 2 mL). After

drying over MgSO_4 , the extracts are concentrated under vacuum. The crude residue is flash chromatographed (silica, 10% methanol/ CH_2Cl_2).

Preparation 3

5 Diethyl 2-(((2-Bromopyrimidin-5-yl)amino)methylene)malonate (N.2).

A mixture of 2-bromopyrimidin-5-amine (Krchnak, V.; Arnold, Z. *Coll. Czech. Chem. Commun.* **1975**, *40*, 1396-1402) (3.48 g) and diethyl ethoxymethylenemalonate (5.05 mL) is heated to 135 °C for 1 h. The mixture is allowed to cool affording a
10 solid.

Preparation 4

Ethyl 8-Bromo-2-hydroxypyrido[3,2-*d*]pyrimidine-7-carboxylate (N.3).

15 A suspension of diethyl 2-(((2-bromopyrimidin-5-yl)amino)methylene)malonate (Preparation 3, 1.72 g) in diethylphthalate (50 mL) is purged with nitrogen and then heated to reflux with collection of ethanol in a Dean-Stark trap. After no additional distillate is observed, the mixture is allowed to cool to room temperature and is poured into tert-butyl methylether (250 mL). The resulting precipitate is collected
20 and dried.

Preparation 5

8-Bromo-2-hydroxypyrido[3,2-*d*]pyrimidine-7-carboxylic Acid (N.4).

25 A suspension of ethyl 8-bromo-2-hydroxypyrido[3,2-*d*]pyrimidine-7-carboxylate (Preparation 4, 1.49 g) and 10% aqueous sodium hydroxide solution (40 mL) is heated at reflux until ester is consumed. The mixture is allowed to cool to room temperature and is made acidic with 50% aqueous HCl solution. The resulting precipitate is collected and dried.

30

Preparation 6


2-Bromo-*N*-(4-chlorobenzyl)-8-hydroxypyrido[3,2-*d*]pyrimidine-7-carboxamide (N.5, X = chloro).

- 5 A mixture of 8-bromo-2-hydroxypyrido[3,2-*d*]pyrimidine-7-carboxylic acid (Preparation 5, 1.35 g) and 1,1'-carbonyldiimidazole (1.05 g) in DMF (45 mL) is heated to 60 °C overnight. The reaction mixture is allowed to cool to room temperature and 4-chlorobenzylamine (0.8 mL) is added. The mixture is allowed to stir for 7 h and is then poured into 20% aqueous acetic acid (100 mL). The resulting
10 precipitate is collected and dried.

Example 2

N-(4-Chlorobenzyl)-8-hydroxy-2-(3-hydroxyprop-1-ynyl)pyrido[3,2-*d*]pyrimidine-7-carboxamide (N.6, X = chloro, Z = CH₂OH).

15



- A mixture of 2-bromo-*N*-(4-chlorobenzyl)-8-hydroxypyrido[3,2-*d*]pyrimidine-7-carboxamide (Preparation 6, 1.97 g), (Ph₃P)₂PdCl₂ (175 mg), and triethylamine (5.0
20 mL) in DMF (50 mL) is heated to 90 °C. Propargyl alcohol (2.5 mL) is slowly added to the mixture over 20 h. The reaction mixture is allowed to cool to room temperature, poured into saturated aqueous NH₄Cl solution (200 mL), and extracted with ethyl acetate (3 x 100 mL). The combined organic layers are dried (MgSO₄) and concentrated. The crude product is purified by column chromatography.

25

Preparation 7

N-(3-Bromo-6-carboxybenzylidene)-*B*,*B*-diethylboroxazolidone (S.2).

- Freshly prepared 2-aminoacetic acid diethyl borate (Nefkens, G. H. L.; Zwanenburg,
30 *B. Tetrahedron* **1983**, 39, 2995) (1.43 g) is suspended in benzene (100 mL). 5-Bromo-2-formylbenzoic acid (US Patent 3,45,003) (2.29 g) is added to the mixture and it is then heated at reflux employing a Dean-Stark trap until no further water is removed. The mixture is filtered and concentrated.

Preparation 8

6-Bromo-4-hydroxyisoquinoline-3-carboxylic Acid (S.3).

5 To a solution of *N*-(3-bromo-6-carboxybenzylidene)-*B,B*-diethylboroxazolidone (Preparation 7, 3.53 g) in dry DMF (50 mL) is added potassium tert-butoxide (1.12 g). The mixture is cooled to -20 °C and dimethyl sulfate (1.26 g) is added gradually. The mixture is stirred overnight and then concentrated. Water is added to the residue and the solid is filtered. A portion of the resulting ester (1.84 g) is dissolved in dry DMF
10 and the solution is cooled to -40 °C. Potassium tert-butoxide (0.56 g) is added. The mixture is allowed to warm to room temperature and is then slowly poured into aqueous citric acid. The resulting precipitate is filtered and washed with water. The solids are dissolved in a mixture of acetic acid/conc. hydrochloric acid (1/1, 10 mL) with gentle heating. The solvent is then removed in vacuo. The remaining solids are
15 dissolved in ethanol/water (1/1) and neutralized with pyridine. The resulting solid is filtered.


Preparation 9

6-Bromo-*N*-(4-chlorobenzyl)-4-hydroxyisoquinoline-3-carboxamide (S.4, X =
20 chloro).

A mixture of 6-bromo-4-hydroxyisoquinoline-3-carboxylic acid (Preparation 8, 0.4 g), 4-chlorobenzylamine (0.219 g), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.305 g) and 1-hydroxybenzotriazole monohydrate (0.217 g) in DMF
25 (20 mL) is stirred at room temperature until judged complete. The solution is then poured into ice water and the resulting solid collected and dried.

Example 3

N-(4-Chlorobenzyl)-4-hydroxy-6-(3-hydroxyprop-1-ynyl)isoquinoline-3-carboxamide
30 (Q.1, X = chloro, A = CH, Z = CH₂OH).



A mixture of 6-bromo-*N*-(4-chlorobenzyl)-4-hydroxyisoquinoline-3-carboxamide (Preparation 9, 1.96 g), (Ph₃P)₂PdCl₂ (175 mg), and triethylamine (5.0 mL) in DMF (50 mL) is heated to 90 °C. Propargyl alcohol (2.5 mL) is slowly added to the mixture over 20 h. The reaction mixture is allowed to cool to room temperature, poured into saturated aqueous NH₄Cl solution (200 mL), and extracted with ethyl acetate (3 x 100 mL). The combined organic layers are dried (MgSO₄) and concentrated. The crude product is purified by column chromatography.

Preparation 10

10 Ethyl 2-(Bromomethyl)-5-iodonicotinate (**P.2**).

A mixture of ethyl 5-iodo-2-methylnicotinate (*J. Am. Chem. Soc.* **1953**, *75*, 737-738) (7.28 g), *N*-bromosuccinimide (4.54 g), benzoyl peroxide (0.3 g), and tetrachloromethane (100 mL) is refluxed for 6 h. The mixture is allowed to cool to room temperature and is filtered through silica washing with additional tetrachloromethane. The solvent is removed in vacuo to afford the crude bromide.

Preparation 11

20 Ethyl 2-(((2-Ethoxy-2-oxoethyl)((4-methylphenyl)sulfonyl)amino)methyl)-5-iodonicotinate (**P.3**).

Ethyl 2-(bromomethyl)-5-iodonicotinate (Preparation 10, 9.25 g) and ethyl (((4-methylphenyl)sulfonyl)amino)acetate (7.0 g) are dissolved in anhydrous ethanol (50 mL) and a solution of sodium ethoxide (3.4 g) in ethanol (45 mL) is added over 15 min. The mixture is stirred overnight and then poured into ice water. The mixture is extracted with ethyl acetate (3 x 100 mL) and the organic layer is concentrated.

Preparation 12

30 Ethyl 5-Hydroxy-3-iodo[1,7]naphthyridine-6-carboxylate (**P.4**).

A mixture of ethyl 2-(((2-ethoxy-2-oxoethyl)((4-methylphenyl)sulfonyl)amino)-methyl)-5-iodonicotinate (Preparation 11, 8.20 g) and sodium ethoxide (2.6 g) in anhydrous ethanol (60 mL) is stirred for 5 h. The mixture is then poured into water

and neutralized with 3 N aqueous hydrochloric acid. The resulting precipitate is filtered and dried.

Preparation 13


5 *N*-(4-Chlorobenzyl)-5-hydroxy-3-iodo[1,7]naphthyridine-6-carboxamide (P.5).

A suspension of ethyl 5-hydroxy-3-iodo[1,7]naphthyridine-6-carboxylate (Preparation 12, 1.72 g) and 10% aqueous sodium hydroxide solution (40 mL) is heated at reflux until ester is consumed. The mixture is allowed to cool to room temperature and is
10 made acidic with 50% aqueous HCl solution. The resulting precipitate is collected and dried. A mixture of the resulting acid (0.47 g), 4-chlorobenzylamine (0.219 g), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.305 g) and 1-hydroxybenzotriazole monohydrate (0.217 g) in DMF (20 mL) is stirred at room temperature until judged complete. The solution is then poured into ice water and the
15 resulting solid collected and dried.

Example 4

N-(4-Chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)[1,7]naphthyridine-6-carboxamide (Q.1, X = chloro, A = N, Z = CH₂OH).

20



A mixture of *N*-(4-chlorobenzyl)-5-hydroxy-3-iodo[1,7]naphthyridine-6-carboxamide (Preparation 13, 2.20 g), (Ph₃P)₂PdCl₂ (175 mg), and triethylamine (5.0 mL) in DMF
25 (50 mL) is heated to 90 °C. Propargyl alcohol (2.5 mL) is slowly added to the mixture over 20 h. The reaction mixture is allowed to cool to room temperature, poured into saturated aqueous NH₄Cl solution (200 mL), and extracted with ethyl acetate (3 x 100 mL). The combined organic layers are dried (MgSO₄) and concentrated. The crude product is purified by column chromatography.

30

Testing of Inventive Compounds

The antiviral activity of a compound of the invention can be determined using pharmacological models which are well known to the art, or using the test described below.

5

While many of the compounds of the present invention can demonstrate activity against the CMV polymerase, these compounds may be active against the cytomegalovirus by this or other mechanisms of action. Thus, the description below of these compounds' activity against the CMV polymerase is not meant to limit the present invention to a specific mechanism of action.

10

The HCMV polymerase assay is performed using a scintillation proximity assay (SPA) as described in several references, such as N.D. Cook, et al., Pharmaceutical Manufacturing International, pages 49-53 (1992); K. Takeuchi, Laboratory Practice, September issue (1992); US Patent No. 4,568,649 (1986); which are incorporated by reference herein. Reactions are performed in 96-well plates. The assay is conducted in 100 μ l volume with 5.4 mM HEPES (pH 7.5), 11.7 mM KCl, 4.5 mM $MgCl_2$, 0.36 mg/ml BSA, and 90 nM 3H -dTTP. Assays are run with and without CHAPS, (3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane-sulfonate) at a final concentration of 2 mM. HCMV polymerase is diluted in enzyme dilution buffer containing 50% glycerol, 250 mM NaCl, 10 mM HEPES (pH 7.5), 100 μ g/ml BSA, and 0.01% sodium azide. The HCMV polymerase, which is expressed in recombinant baculovirus-infected SF-9 cells and purified according to literature procedures, is added at 10% (or 10 μ l) of the final reaction volume, i.e., 100 μ l. Compounds are diluted in 50% DMSO and 10 μ l are added to each well. Control wells contain an equivalent concentration of DMSO. Unless noted otherwise, reactions are initiated via the addition of 6 nM biotinylated poly(dA)-oligo(dT) template/primer to reaction mixtures containing the enzyme, substrate, and compounds of interest. Plates are incubated in a 25 °C or 37 °C water bath and terminated via the addition of 40 μ l/reaction of 0.5 M EDTA (pH 8) per well. Reactions are terminated within the time-frame during which substrate incorporation is linear and varied depending upon the enzyme and conditions used, i.e., 30 min. for HCMV polymerase. Ten μ l of streptavidin-SPA beads (20 mg/ml in PBS/10% glycerol) are added following

25

30


termination of the reaction. Plates are incubated 10 min. at 37 °C, then equilibrated to room temperature, and counted on a Packard Topcount. Linear regressions are performed and IC₅₀'s are calculated using computer software.

- 5 A modified version of the above HCMV polymerase assay is performed as described above, but with the following changes: Compounds are diluted in 100% DMSO until final dilution into assay buffer. In the previous assay, compounds are diluted in 50% DMSO. 4.5 mM dithiotherotol (DTT) is added to the polymerase buffer. Also, a different lot of CMV polymerase is used, which appears to be more active resulting in
10 a more rapid polymerase reaction.

Having described the invention in detail and by reference to the preferred embodiments thereof, it will be apparent that modifications and variations are possible without departing from the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A compound of formula I,



(I)

wherein,

X is Cl, Br, F, CN or NO₂;

G is (a) C₁₋₇alkyl which partially unsaturated and is substituted by hydroxy, or

10 (b) C₁₋₄alkyl substituted by NR¹R² or 4-tetrahydropyran;


R¹ is C₂₋₇alkyl substituted by hydroxy, C₁₋₄alkoxy, aryl, or heteroaryl;

R² is hydrogen or C₁₋₇alkyl;


or R¹ and R² together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C₁₋₇alkyl;

15


W is a heterocycle of formula W1, W3, or W4;



W1



W3



W4

20

A is CR⁴ or nitrogen;

B is CR⁵ or nitrogen;

C is CR⁶ or nitrogen;

25 E and F are such that

(a) one is oxygen and the other is C(=O); or

(b) E is C(=O) and F is NR⁷;

J and K are such that

(a) J is nitrogen and K is CR⁸; or

(b) J is CR⁶ and K is nitrogen;

30 with the provisos that when W is of formula W3 and J is nitrogen, then at least one of A and B is nitrogen;

R⁴ is H, halogen, or C₁₋₄alkyl optionally substituted by one to three halogens;

R⁵ is (a) H,

- (b) halo,
- (c) OR^{12} ,
- (d) SR^{12} ,
- 5 (e) C_{1-7} alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12} , SR^{12} , $NR^{10}R^{11}$, or halo,
- (f) C_{3-8} cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12} , SR^{12} , or $NR^{10}R^{11}$,
- 10 (g) $(C=O)R^9$,
- (h) $S(O)_mR^9$,
- (i) $(C=O)OR^2$,
- (j) $NHSO_2R^9$,
- (k) nitro, or
- (l) cyano;
- 15 R^6 is (a) H,
- (b) halo,
- (c) aryl,
- (d) het,
- (e) OR^{12} ,
- 20 (f) SR^{12} ,
- (g) C_{1-7} alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12} , SR^{12} , $NR^{10}R^{11}$, aryl, halo, C_{3-8} cycloalkyl optionally substituted by OR^{12} , or het attached through a carbon atom,
- 25 (h) $NR^{10}R^{11}$,
- (i) C_{3-8} cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12} , SR^{12} , or $NR^{10}R^{11}$,
- (j) $(C=O)R^9$,
- 30 (k) $S(O)_mR^9$,
- (l) $(C=O)OR^2$,
- (m) $NHSO_2R^9$,
- (n) nitro, or

- (o) cyano;
- R⁷ is (a) H,
- (b) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
- 5 (c) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,
- (d) aryl, or
- (e) het;
- 10 R⁸ is (a) H,
- (b) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
- (c) OR¹², or
- (d) SR¹²;
- 15 R⁹ is (a) C₁₋₇alkyl,
- (b) NR¹⁰R¹¹,
- (c) aryl, or
- (d) het, wherein said het is bound through a carbon atom;
- R¹⁰ and R¹¹ are independently
- 20 (a) H,
- (b) aryl,
- (c) C₁₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR²R², CO₂R², het, aryl, cyano, or halo,
- 25 (d) C₂₋₇alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR²R², OR², or SR²,
- (e) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R², or
- 30 (f) R¹⁰ and R¹¹ together with the nitrogen to which they are attached form a het;
- R¹² is (a) H,
- (b) aryl,

- (c) het
- (d) C₁₋₇alkyl optionally substituted by aryl, het, or halogen,
- (e) C₂₋₇alkyl substituted by OR², SR², or NR²R², or
- 5 (f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R²;

each m is independently 1 or 2;

- 10 aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR²R², CO₂R², CF₃, C₁₋₆alkoxy, and C₁₋₆alkyl which maybe further substituted by one to three SR², NR²R², OR², or CO₂R² groups;

15

- het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected
- 20 from halo, OH, cyano, phenyl, CO₂R², CF₃, C₁₋₆alkoxy, oxo, oxime, and C₁₋₆alkyl which may be further substituted by one to three SR², NR²R², OR², or CO₂R² groups;

halo or halogen is F, Cl, Br, I;

- 25 1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);

- 30 and a pharmaceutically acceptable salt thereof;

2. A compound of claim 1 wherein W is of the formula W1.

3. A compound of claim 2 wherein W is of the formula W1.1.
4. A compound of claim 2 wherein W is of the formula W1.2.
- 5 5. A compound of claim 2 wherein W is of the formula W1.3.
6. A compound of claim 2 wherein W is of the formula W1.4.
7. A compound of claim 2 wherein W is of the formula W1.5.
- 10 8. A compound of claim 2 wherein W is of the formula W1.6.
9. A compound of claim 2 wherein W is of the formula W1.7.
- 15 10. A compound of claim 2 wherein W is of the formula W1.8.
11. A compound of claim 2 wherein W is of the formula W1.9.
12. A compound of claim 2 wherein W is of the formula W1.10.
- 20 13. A compound of claim 2 wherein W is of the formula W1.11.
14. A compound of claim 2 wherein W is of the formula W1.12.
- 25 15. A compound of claim 2 wherein W is of the formula W1.13.
16. A compound of claim 2 wherein W is of the formula W1.14.
17. A compound of claim 2 wherein W is of the formula W1.15.
- 30 18. A compound of claim 2 wherein W is of the formula W1.16.
19. A compound of claim 2 wherein W is of the formula W1.17.

20. A compound of claim 2 wherein W is of the formula W1.18.
21. A compound of claim 2 wherein W is of the formula W1.19.
- 5 22. A compound of claim 2 wherein W is of the formula W1.20.
23. A compound of claim 2 wherein W is of the formula W1.21.
- 10 24. A compound of claim 2 wherein W is of the formula W1.22.
25. A compound of claim 2 wherein W is of the formula W1.23.
26. A compound of claim 1 wherein W is of the formula W3.
- 15 27. A compound of claim 26 wherein W is of the formula W3.1.
28. A compound of claim 26 wherein W is of the formula W3.2.
- 20 29. A compound of claim 26 wherein W is of the formula W3.3.
30. A compound of claim 26 wherein W is of the formula W3.4.
31. A compound of claim 26 wherein W is of the formula W3.5.
- 25 32. A compound of claim 26 wherein W is of the formula W3.6.
33. A compound of claim 26 wherein W is of the formula W3.7.
- 30 34. A compound of claim 26 wherein W is of the formula W3.8.
35. A compound of claim 26 wherein W is of the formula W3.9.

36. A compound of claim 26 wherein W is of the formula W3.10.
37. A compound of claim 26 wherein W is of the formula W3.11.
- 5 38. A compound of claim 26 wherein W is of the formula W3.12.
39. A compound of claim 26 wherein W is of the formula W3.13.
40. A compound of claim 26 wherein W is of the formula W3.14.
- 10 41. A compound of claim 1 wherein W is of the formula W4.
42. The compound according to claim 1, wherein X is Cl.
- 15 43. The compound according to claim 1 wherein G is 4-morpholinylmethyl.
44. The compound according to claim 1 wherein G is 3-hydroxy-1-propynyl.
45. The compound according to claim 1 wherein G is tetrahydro-2*H*-pyran-4-ylmethyl.
- 20 46. The compound according to claim 1 which is
N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-2-oxo-2*H*-pyrano[2,3-*c*]pyridine-3-carboxamide;
- 25 *N*-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1*H*-isochromene-3-carboxamide;
- N*-(4-chlorobenzyl)-4-hydroxy-1-oxo-6-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-
- 30 isochromene-3-carboxamide;
- N*-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1*H*-isochromene-3-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)-8-oxo-7,8-dihydro[1,7]-naphthyridine-6-carboxamide;

- 5 *N*-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxamide;

10

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]naphthyridine-3-carboxamide;

- 15 *N*-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]-naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-carboxamide;

- 20 *N*-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,5]naphthyridine-3-carboxamide;

25

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,5]naphthyridine-3-carboxamide;

- 30 *N*-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2*H*-pyran-4-ylmethyl)[1,5]-naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-8-hydroxy-2-(3-hydroxy-1-propynyl)pyrido[3,2-*d*]pyrimidine-7-carboxamide;

N-(4-chlorobenzyl)-8-hydroxy-2-(4-morpholinylmethyl)pyrido[3,2-*d*]pyrimidine-7-carboxamide;

- 5 *N*-(4-chlorobenzyl)-5-hydroxy-3-(4-morpholinylmethyl)[1,7]naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)[1,7]naphthyridine-6-carboxamide;

10

N-(4-chlorobenzyl)-5-hydroxy-3-(tetrahydro-2*H*-pyran-4-ylmethyl)[1,7]-naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-isoquinolinecarboxamide;

15


N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2*H*-pyran-4-ylmethyl)-3-isoquinolinecarboxamide; or

- 20 a pharmaceutically acceptable salt thereof.

47. A pharmaceutical composition comprising a compound of claims 1 to 46 and a pharmaceutically acceptable carrier.

- 25 48. A use of compound of claim 1 to prepare a medicament for treating or preventing a viral infection in a mammal,



30

(I)

wherein,

X is Cl, Br, F, CN or NO₂;

G is (a) C₃₋₇alkyl which is partially unsaturated and is substituted by hydroxy,

(b) C₁₋₇alkyl which is fully saturated and is substituted by hydroxy, or


(c) C₁₋₄alkyl substituted by NR¹R² or 4-tetrahydropyran;

R¹ is C₂₋₇alkyl substituted by hydroxy, C₁₋₄alkoxy, aryl, or heteroaryl;

R² is hydrogen or C₁₋₇alkyl;

5 or R¹ and R² together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C₁₋₇alkyl;

W is a heterocycle of formula W1, W3, or W4;



A is CR⁴ or nitrogen;

15 B is CR⁵ or nitrogen;

C is CR⁶ or nitrogen;

E and F are such that

(a) one is oxygen and the other is C(=O); or

(b) E is C(=O) and F is NR⁷;

J and K are such that

(a) J is nitrogen and K is CR⁸; or

20

(b) J is CR⁶ and K is nitrogen;

with the provisos that when W is of formula W3 and J is nitrogen, then at least one of A and B is nitrogen;

R⁴ is H, halogen, or C₁₋₄alkyl optionally substituted by one to three halogens;

25 R⁵ is (a) H,

(b) halo,

(c) OR¹²,

(d) SR¹²,

(e) C₁₋₇alkyl which may be partially unsaturated and optionally substituted
30 by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,

(f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,

- (g) $(C=O)R^9$,
 (h) $S(O)_mR^9$,
 (i) $(C=O)OR^2$,
 (j) $NHSO_2R^9$,
 5 (k) nitro, or
 (l) cyano;
- R^6 is (a) H,
 (b) halo,
 (c) aryl,
 10 (d) het,
 (e) OR^{12} ,
 (f) SR^{12} ,
 (g) C_{1-7} alkyl which may be partially unsaturated and optionally substituted
 by one or more substituents selected from OR^{12} , SR^{12} , $NR^{10}R^{11}$, aryl,
 15 halo, C_{3-8} cycloalkyl optionally substituted by OR^{12} , or het attached
 through a carbon atom,
 (h) $NR^{10}R^{11}$,
 (i) C_{3-8} cycloalkyl which may be partially unsaturated and is optionally
 substituted by one or more substituents selected from halogen, OR^{12} ,
 20 SR^{12} , or $NR^{10}R^{11}$,
 (j) $(C=O)R^9$,
 (k) $S(O)_mR^9$,
 (l) $(C=O)OR^2$,
 (m) $NHSO_2R^9$,
 25 (n) nitro, or
 (o) cyano;
- R^7 is (a) H,
 (b) C_{1-7} alkyl which may be partially unsaturated and optionally substituted
 by one or more substituents selected from OR^{12} , SR^{12} , $NR^{10}R^{11}$, or halo,
 30 (c) C_{3-8} cycloalkyl which may be partially unsaturated and is optionally
 substituted by one or more substituents selected from halogen, OR^{12} ,
 SR^{12} , or $NR^{10}R^{11}$,
 (d) aryl, or

- (e) het;
- R⁸ is (a) H,
- (b) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
- 5 (c) OR¹², or
- (d) SR¹²;
- R⁹ is (a) C₁₋₇alkyl,
- (b) NR¹⁰R¹¹,
- (c) aryl, or
- 10 (d) het, wherein said het is bound through a carbon atom;
- R¹⁰ and R¹¹ are independently
- (a) H,
- (b) aryl,
- (c) C₁₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR²R², CO₂R², het, aryl, cyano, or halo,
- 15 (d) C₂₋₇alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR²R², OR², or SR²,
- (e) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R², or
- 20 (f) R¹⁰ and R¹¹ together with the nitrogen to which they are attached form a het;
- R¹² is (a) H,
- 25 (b) aryl,
- (c) het
- (d) C₁₋₇alkyl optionally substituted by aryl, het, or halogen,
- (e) C₂₋₇alkyl substituted by OR², SR², or NR²R², or
- 30 (f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R²;

each m is independently 1 or 2;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR^2R^2 , CO_2R^2 , CF_3 , C_{1-6} alkoxy, and C_{1-6} alkyl which maybe further substituted by one to three SR^2 , NR^2R^2 , OR^2 , or CO_2R^2 groups;

het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO_2R^2 , CF_3 , C_{1-6} alkoxy, oxo, oxime, and C_{1-6} alkyl which may be further substituted by one to three SR^2 , NR^2R^2 , OR^2 , or CO_2R^2 groups;

halo or halogen is F, Cl, Br, I;

1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);

and a pharmaceutically acceptable salt thereof;

49. A use according to claim 48 wherein said viral infection is a herpes virus infection.

50. A use according to claim 48 wherein said mammal is a human.

51. A use according to claim 48 wherein said mammal is a food animal or companion animal.

52. A use according to claim 48 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type, 6, 7, or 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.

5 53. A use according to claim 48 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.


54. A use according to claim 48 wherein the amount administered is from about
10 0.1 to about 300 mg/kg of body weight.

55. A use according to claim 48 wherein the amount administered is from about 1 to about 30 mg/kg of body weight.

15 56. A use according to claim 48 wherein the compound is administered parenterally, topically, intravaginally, orally, or rectally.

57. A use for inhibiting a viral DNA polymerase, comprising contacting the polymerase with an effective inhibitory amount of a compound of the formula (I)

20



(I)

wherein,

25 X is Cl, Br, F, CN or NO₂;


G is (a) C₃₋₇alkyl which is partially unsaturated and is substituted by hydroxy,
(b) C₁₋₇alkyl which is fully saturated and is substituted by hydroxy, or
(c) C₁₋₄alkyl substituted by NR¹R² or 4-tetrahydropyran;

R¹ is C₂₋₇alkyl substituted by hydroxy, C₁₋₄alkoxy, aryl, or heteroaryl;

30 R² is hydrogen or C₁₋₇alkyl;

or R¹ and R² together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C₁₋₇alkyl;

W is a heterocycle of formula W1, W3, or W4;



5

A is CR⁴ or nitrogen;

B is CR⁵ or nitrogen;

C is CR⁶ or nitrogen;

10 E and F are such that (a) one is oxygen and the other is C(=O); or

(b) E is C(=O) and F is NR⁷;

J and K are such that (a) J is nitrogen and K is CR⁸; or

(b) J is CR⁶ and K is nitrogen;

15 with the provisos that when W is of formula W3 and J is nitrogen, then at least one of A and B is nitrogen;

R⁴ is H, halogen, or C₁₋₄alkyl optionally substituted by one to three halogens;

R⁵ is (a) H,

(b) halo,

20 (c) OR¹²,

(d) SR¹²,

(e) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,

(f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,

25

(g) (C=O)R⁹,

(h) S(O)_mR⁹,

(i) (C=O)OR²,

30

(j) NHSO₂R⁹,

(k) nitro, or

(l) cyano;

R⁶ is (a) H,

- (b) halo,
 (c) aryl,
 (d) het,
 (e) OR^{12} ,
 5 (f) SR^{12} ,
 (g) C_{1-7} alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12} , SR^{12} , $NR^{10}R^{11}$, aryl, halo, C_{3-8} cycloalkyl optionally substituted by OR^{12} , or het attached through a carbon atom,
 10 (h) $NR^{10}R^{11}$,
 (i) C_{3-8} cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12} , SR^{12} , or $NR^{10}R^{11}$,
 (j) $(C=O)R^9$,
 15 (k) $S(O)_mR^9$,
 (l) $(C=O)OR^2$,
 (m) $NHSO_2R^9$,
 (n) nitro, or
 (o) cyano;
 20 R^7 is (a) H,
 (b) C_{1-7} alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12} , SR^{12} , $NR^{10}R^{11}$, or halo,
 (c) C_{3-8} cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12} ,
 25 SR^{12} , or $NR^{10}R^{11}$,
 (d) aryl, or
 (e) het;
 R^8 is (a) H,
 (b) C_{1-7} alkyl which may be partially unsaturated and optionally substituted
 30 by one or more substituents selected from OR^{12} , SR^{12} , $NR^{10}R^{11}$, or halo,
 (c) OR^{12} , or
 (d) SR^{12} ;
 R^9 is (a) C_{1-7} alkyl,

- (b) $\text{NR}^{10}\text{R}^{11}$,
- (c) aryl, or
- (d) het, wherein said het is bound through a carbon atom;

R^{10} and R^{11} are independently

- 5 (a) H,
 - (b) aryl,
 - (c) C_{1-7} alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR^2R^2 , CO_2R^2 , het, aryl, cyano, or halo,
 - 10 (d) C_{2-7} alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR^2R^2 , OR^2 , or SR^2 ,
 - (e) C_{3-8} cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^2 , SR^2 , or NR^2R^2 , or
 - 15 (f) R^{10} and R^{11} together with the nitrogen to which they are attached form a het;
- R^{12} is
- (a) H,
 - (b) aryl,
 - (c) het
 - 20 (d) C_{1-7} alkyl optionally substituted by aryl, het, or halogen,
 - (e) C_{2-7} alkyl substituted by OR^2 , SR^2 , or NR^2R^2 , or
 - (f) C_{3-8} cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^2 , SR^2 , or NR^2R^2 ;

25

each m is independently 1 or 2;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more

30 substituents selected from halo, OH, cyano, NR^2R^2 , CO_2R^2 , CF_3 , C_{1-6} alkoxy, and C_{1-6} alkyl which maybe further substituted by one to three SR^2 , NR^2R^2 , OR^2 , or CO_2R^2 groups;

het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected
5 from halo, OH, cyano, phenyl, CO_2R^2 , CF_3 , C_{1-6} alkoxy, oxo, oxime, and C_{1-6} alkyl which may be further substituted by one to three SR^2 , NR^2R^2 , OR^2 , or CO_2R^2 groups;

halo or halogen is F, Cl, Br, I;

10 1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);

15 and a pharmaceutically acceptable salt thereof;

58. A use of claim 57 wherein the polymerase and the compound are contacted *in vitro*.

20 59. A use of claim 57 wherein the polymerase and the compound are contacted *in vivo*.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/004443 A3

(51) International Patent Classification⁷: **C07D 271/26**,
311/56, 311/76, 487/04, 491/107, A61K 31/37, 31/436,
31/4375, 31/47, 31/495, 31/519, A61P 31/22

(74) Agent: YANY, Lucy, X.; Intellectual Property Legal Ser-
vices, Pharmacia & Upjohn Company, 301 Henrietta Street,
Kalamazoo, MI 49001 (US).

(21) International Application Number: PCT/US01/16492

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(22) International Filing Date: 25 June 2001 (25.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/217,556 12 July 2000 (12.07.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): PHAR-
MACIA & UPJOHN COMPANY [US/US]; 301 Henri-
etta Street, Kalamazoo, MI 49001 (US).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SCHNUTE, Mark,
E. [US/US]; 4459 Wimbleton Way, Kalamazoo, MI
49009 (US). VAILLANCOURT, Valerie, A. [US/US];
4342 Bronson Boulevard, Kalamazoo, MI 49008 (US).
LARSEN, Scott, D. [US/US]; 56 Naples Court, Kalama-
zoo, MI 49009 (US).


(88) Date of publication of the international search report:
12 September 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 02/004443 A3

(54) Title: HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS

(57) Abstract: The present invention provides a compound of for-
mula I which is useful as antiviral agents, in particular, as agents
against viruses of the herpes family.



(I)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/16492

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D217/26 C07D311/56 C07D311/76 C07D487/04 C07D491/107
 A61K31/37 A61K31/436 A61K31/4375 A61K31/47 A61K31/495
 A61K31/519 A61P31/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 99 32450 A (STROHBACH JOSEPH WALTER ;UPJOHN CO (US); SCHNUTE MARK E (US); TURN) 1 July 1999 (1999-07-01) cited in the application page 1, line 7,8 page 11, formula I page 11, line 23,24,26,27,35 page 12, line 12,13,22-25 examples 53,94,96,101,104,107,115,118,121,122,134-1 37,152</p> <p style="text-align: center;">--- -/--</p>	1-59



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

16 January 2002

Date of mailing of the international search report

23/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hoepfner, W

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/16492

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 11073 A (TUCKER JOHN A ;UPJOHN CO (US); ROMERO ARTHUR G (US); ROMINES KAREN) 19 March 1998 (1998-03-19) abstarct, formula IA page 1, line 9,10 page 6, line 25,26 page 7, line 2,3,12,19,21-24,33 page 9, line 6,9,11,12,19,33,34 examples 46,51,53,55,68 -----	1-59

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/16492

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9932450	A	01-07-1999	AU 1606399 A	12-07-1999
			CN 1281439 T	24-01-2001
			EP 1042295 A1	11-10-2000
			HU 0101999 A2	28-11-2001
			NO 20003233 A	22-08-2000
			PL 341364 A1	09-04-2001
			SK 9072000 A3	12-03-2001
			WO 9932450 A1	01-07-1999
			US 6093732 A	25-07-2000
WO 9811073	A	19-03-1998	AU 4172197 A	02-04-1998
			EP 0927164 A1	07-07-1999
			WO 9811073 A1	19-03-1998
			US 6252080 B1	26-06-2001
			US 6211376 B1	03-04-2001
			US 6310211 B1	30-10-2001